Methandienone 20mg (Dianabol)

Methandienone 20mg (Dianabol) | iRoids Pharma

Methandienone 20mg is an oral anabolic steroid containing 20mg of Methandienone per tablet. At iRoids Pharma, we carry Methandienone 20mg as part of our oral anabolic steroid inventory for customers in markets where Methandienone is legally available.

Methandienone is the active compound in this preparation. It is the same compound widely known under the brand names Dianabol and Dbol, and also referenced in pharmacological literature as Methandrostenolone. The name Methandienone reflects the systematic chemical nomenclature for this compound and is the designation used across several international pharmaceutical markets where it carried regulatory approval during its period of commercial availability.

The 20mg tablet format represents a mid-range concentration within the iRoids Pharma Methandienone product range, sitting between the conservative 10mg format and the highest-concentration 50mg format. This positioning carries specific pharmacological and practical implications that distinguish the 20mg format from both alternatives. This page covers the pharmacology, concentration-specific context, and health and legal considerations relevant to anyone researching this specific preparation. It does not constitute medical advice, recommend steroid use, or provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

Methandienone and Methandrostenolone: The Same Compound

A note on nomenclature is relevant before discussing this compound’s pharmacology. Methandienone and Methandrostenolone are two names for the same active compound. Methandienone is the International Nonproprietary Name and the designation used in British Pharmacopoeia and several European regulatory frameworks. Methandrostenolone was the name under which CIBA originally developed and marketed the compound. Dianabol is the brand name under which it reached commercial markets globally. All three names consequently refer to identical pharmacological entities and the research literature uses all three designations across different publication contexts.

Understanding this nomenclature distinction is relevant because buyers researching this compound across different sources may encounter all three names and incorrectly conclude they represent different compounds. The iRoids Pharma Methandienone 20mg preparation contains the same active pharmacological entity as any preparation labeled Methandrostenolone or Dianabol at the equivalent concentration.

The 20mg Concentration: Positioning Within the iRoids Pharma Range

The 20mg format occupies a specific position within the iRoids Pharma Methandienone product range that distinguishes it from both the 10mg and 50mg formats available in our catalog.

Relationship to the 10mg Format

The 20mg format delivers exactly double the active compound per tablet compared to the 10mg format. Every dose-dependent pharmacological effect and every dose-dependent side effect is consequently twice as pronounced per tablet at the 20mg concentration as at the 10mg concentration. The 20mg format provides less per-tablet dose precision than the 10mg format but provides a more potent per-tablet delivery for anyone researching higher daily exposure levels of this compound.

Relationship to the 50mg Format

The 50mg format delivers two and a half times the active compound per tablet compared to the 20mg format. Every dose-dependent consideration is consequently two and a half times more pronounced per tablet at the 50mg concentration than at the 20mg format. The 20mg format provides significantly greater per-tablet dose precision than the 50mg format and produces proportionally less pronounced dose-dependent side effects per tablet. For anyone researching Methandienone at iRoids Pharma who wants a balance between potency per tablet and dose precision, the 20mg format consequently occupies the practical middle ground between the two extreme concentrations in our catalog.

Historical Pharmaceutical Reference Context

During the period of pharmaceutical market availability, Methandienone was produced at 5mg and 10mg tablet formats in most markets. The 20mg concentration consequently doubles the upper end of the historical pharmaceutical tablet format. This distinction is directly relevant to how the available clinical research literature, which was accumulated at doses consistent with 5mg and 10mg historical formats, applies to the 20mg concentration. The dose-dependent side effect profile at 20mg per tablet is consequently less well-characterized by the controlled clinical research base than at 10mg formats.

What Is Methandienone

Methandienone is a synthetic anabolic-androgenic steroid derived from testosterone. CIBA Pharmaceuticals developed it in 1955 under the direction of Dr. John Ziegler and introduced it to the US market under the Dianabol brand name in 1958. The compound rapidly achieved global distribution and became the most widely used oral anabolic steroid in existence within years of its introduction, a distinction it has maintained in non-prescription markets despite FDA market withdrawal in 1985.

Structurally, Methandienone carries two key modifications from the testosterone molecule. A methyl group at the 17-alpha carbon position enables oral bioavailability by protecting the compound from hepatic first-pass metabolism. A double bond at the carbon-1 and carbon-2 positions of the steroid A-ring reduces androgenic receptor affinity in non-target tissues relative to testosterone while preserving strong anabolic receptor activation in muscle tissue. These two structural modifications collectively produce an anabolic rating of 90 to 210 and an androgenic rating of 40 to 60 relative to a testosterone baseline of 100.

The compound undergoes significant aromatase-mediated conversion to estradiol, which is the mechanistic basis for the most commonly reported immediate side effects associated with Methandienone use. Furthermore, the 17-alpha alkylation that enables oral bioavailability places direct metabolic stress on hepatocytes throughout the period of use, producing the hepatotoxicity profile documented consistently across the Methandienone clinical literature.

How Methandienone Works

Methandienone reaches systemic circulation in active form following oral administration due to the hepatic protection provided by 17-alpha alkylation. It subsequently interacts with multiple biological systems through several distinct pharmacological mechanisms.

Androgen Receptor Activation in Skeletal Muscle

Methandienone binds to androgen receptors in skeletal muscle tissue and activates receptor-mediated gene transcription programs that regulate protein synthesis, nitrogen retention, and satellite cell activity. The double bond modification at carbon-1 and carbon-2 reduces its affinity for androgen receptors in non-target tissues including skin and hair follicles relative to unmodified testosterone. As a result, the primary anabolic effects are produced in muscle tissue with comparatively less androgenic receptor activation in tissues associated with androgenic side effects.

At the 20mg concentration, androgen receptor activation is twice as pronounced per tablet as at the 10mg format and consequently produces more robust downstream anabolic effects per tablet while also producing proportionally more pronounced androgenic side effects.

Nitrogen Balance

Methandienone produces strongly positive nitrogen balance in skeletal muscle tissue reflecting net protein synthesis dominance over protein breakdown. This mechanism is among the most consistently documented pharmacological effects in the Methandienone clinical literature and represents a primary mechanistic basis for the anabolic observations associated with this compound. At the 20mg concentration, the nitrogen balance effect is twice as pronounced per tablet as at the 10mg format.

Glycogenolysis

Methandienone enhances glycogenolytic activity in muscle tissue, improving the efficiency of glycogen-to-glucose conversion during high-intensity muscular activity. This mechanism adds a metabolic dimension to Methandienone’s pharmacological profile beyond its direct androgen receptor-mediated anabolic effects. The glycogenolytic enhancement at the 20mg concentration is consequently twice as pronounced per tablet as at the 10mg format.

Aromatase-Mediated Estrogen Conversion

Methandienone undergoes significant conversion to estradiol through the aromatase enzyme in peripheral tissues. This estrogenic conversion produces systemic estrogen elevation that drives extracellular fluid retention, stimulates breast glandular tissue, and produces mood-related hormonal effects. At the 20mg concentration, the rate and magnitude of estrogenic conversion is twice as pronounced per tablet as at the 10mg format and consequently requires proportionally more active estrogen management consideration.

IGF-1 Production

Methandienone stimulates Insulin-like Growth Factor 1 production through androgen receptor-mediated mechanisms. IGF-1 functions as a downstream anabolic mediator in muscle tissue, activating satellite cells, stimulating protein synthesis, and contributing to tissue repair processes. This secondary anabolic pathway amplifies the direct androgen receptor-mediated effects and is proportionally more active at the 20mg concentration than at the 10mg format.

Clinical Background

Methandienone carries an extensively documented clinical history accumulated during its period of pharmaceutical market availability from 1958 through 1985. This clinical background is more extensive than most oral anabolic steroids discussed in performance communities carry.

Original Clinical Development

CIBA developed Methandienone with specific clinical applications in mind including treatment of hypogonadism, osteoporosis, and conditions associated with accelerated protein catabolism. The FDA approved it for these indications and it remained commercially available in the United States until 1985 when CIBA discontinued marketing following regulatory pressure.

Research Literature Accumulated During Pharmaceutical Availability

The clinical and research literature from the 1958 to 1985 period covers Methandienone’s effects on nitrogen balance, protein synthesis, bone density, red blood cell production, and multiple organ systems across various patient populations. This research base was accumulated primarily at doses consistent with the 5mg and 10mg historical pharmaceutical formats. As a result, the 20mg concentration is at the edge of what the controlled research literature directly characterizes, making the clinical research base less directly applicable to the 20mg format than to the 10mg format.

Post-Market Withdrawal Observational Context

Following FDA market withdrawal in 1985, controlled clinical research on Methandienone became limited due to its controlled substance classification. The research base is consequently supplemented by extensive observational data from non-prescription market use across multiple decades. This observational data provides pharmacological context that extends beyond the controlled research literature, particularly for the higher concentration formats that exceed historical pharmaceutical dosing.

Methandienone 20mg Versus Related Compounds at iRoids Pharma

Versus Methandienone 10mg at iRoids Pharma

Both formats contain the same active Methandienone compound with identical pharmacological mechanisms. The 20mg format delivers double the active compound per tablet compared to the 10mg format. Every dose-dependent pharmacological effect and side effect is consequently twice as pronounced per tablet at the 20mg concentration. The 10mg format provides greater dose precision and more conservative per-tablet exposure. The 20mg format provides more potent per-tablet delivery for anyone researching higher daily exposure levels of this compound.

Versus Methandienone 50mg at iRoids Pharma

The 50mg format delivers two and a half times the active compound per tablet compared to the 20mg format. Every dose-dependent consideration is consequently two and a half times more pronounced per tablet at the 50mg concentration. The 20mg format provides significantly greater precision and proportionally less pronounced per-tablet side effects than the 50mg format while delivering more potent per-tablet activity than the 10mg format.

Versus Mesterolone 25mg at iRoids Pharma

Mesterolone 25mg is a non-17-alpha alkylated oral androgen with no aromatization, low hepatotoxicity, and minimal HPG suppression. Methandienone 20mg, by contrast, is a 17-alpha alkylated oral anabolic steroid with significant aromatization, meaningful hepatotoxicity, and HPG suppression. These two compounds represent fundamentally opposite pharmacological profiles. Methandienone 20mg is primarily anabolic with significant estrogenic and hepatotoxic considerations. Mesterolone 25mg is primarily androgenic and ancillary with minimal estrogenic and hepatotoxic considerations. They are pharmacologically complementary rather than directly comparable compounds.

Versus Oxandrolone 10mg at iRoids Pharma

Oxandrolone 10mg is a non-aromatizing 17-alpha alkylated oral anabolic steroid with mild to moderate liver toxicity and active FDA approval. Methandienone 20mg aromatizes significantly to estrogen, carries more pronounced hepatotoxicity than Oxandrolone, and delivers double the per-tablet concentration of the standard Oxandrolone format. These compounds consequently carry different pharmacological profiles despite both being 17-alpha alkylated oral anabolic steroids, with Methandienone 20mg representing a more potent and more estrogenically active profile.

Side Effects and Health Risks

Methandienone 20mg carries a well-documented side effect profile based on decades of clinical observations and research literature. The 20mg concentration makes every dose-dependent consideration twice as pronounced per tablet as the 10mg format and proportionally less pronounced than the 50mg format.

Hepatotoxicity

Hepatotoxicity is the most clinically significant health risk associated with Methandienone use at any concentration. The 17-alpha alkylation places direct metabolic stress on hepatocytes. At the 20mg concentration, hepatic stress is twice as pronounced per tablet as at the 10mg format. Elevated liver transaminase values, cholestatic effects, and in cases of prolonged use more serious structural hepatic complications are documented in the clinical literature. Biochemical liver function monitoring is consequently an essential health consideration for anyone using this compound.

Estrogenic Effects

Aromatase-mediated conversion to estradiol produces the most commonly reported immediate side effects of Methandienone use. Extracellular fluid retention, breast glandular tissue stimulation, and mood-related hormonal effects are all downstream consequences of estrogen elevation. At the 20mg concentration, estrogenic conversion and its downstream effects are twice as pronounced per tablet as at the 10mg format. Aromatase inhibitor co-administration is commonly referenced in performance community discussions as an estrogen management approach with Methandienone use at any concentration.

Cardiovascular Effects

Methandienone produces adverse lipid profile modifications including HDL suppression and LDL elevation documented consistently across the clinical literature. Water retention from estrogenic conversion additionally produces blood pressure elevation through increased circulating volume. At the 20mg concentration, these cardiovascular considerations are twice as pronounced per tablet as at the 10mg format. Active cardiovascular monitoring is consequently essential for anyone using this compound.

HPG Axis Suppression

Methandienone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback on gonadotropin-releasing hormone secretion. At the 20mg concentration, HPG suppression is twice as pronounced per tablet as at the 10mg format. Post-use HPG axis recovery varies in duration and completeness depending on prior use duration and magnitude.

Androgenic Effects

Despite its comparatively reduced androgenic rating, Methandienone still produces androgenic effects in susceptible individuals. Accelerated androgenetic alopecia and acne vulgaris are the most consistently reported androgenic effects. In women, virilization represents serious and potentially irreversible consequences at any concentration of this compound.

Legal and Regulatory Status

Methandienone carries Schedule III controlled substance status in the United States under the Anabolic Steroid Control Act. The FDA withdrew its market approval in 1985. Possession without a valid prescription consequently constitutes a federal offense.

In the United Kingdom, Methandienone is classified as a Class C controlled substance under the Misuse of Drugs Act. Unauthorized supply is a criminal offense.

The World Anti-Doping Agency includes Methandienone on its prohibited list across all competitive sport categories. Urinary detection of Methandienone metabolites is possible for extended periods following cessation of use.

You are responsible for confirming the legal status of Methandienone in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Methandienone the Same as Dianabol and Methandrostenolone

Yes. Methandienone, Methandrostenolone, and Dianabol all refer to the same active pharmacological compound. Methandienone is the International Nonproprietary Name. Methandrostenolone was the original CIBA designation. Dianabol is the brand name under which it reached commercial markets. All three names consequently describe the same compound at the same pharmacological activity level.

Is Methandienone 20mg Available at iRoids Pharma

Yes. iRoids Pharma carries Methandienone 20mg for customers in markets where Methandienone is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Half-Life of Methandienone

Methandienone produces a half-life of approximately 3 to 6 hours. As a result, its relatively short half-life requires regular daily administration to maintain stable plasma concentrations throughout the day. This pharmacokinetic characteristic applies equally across all Methandienone concentration formats.

How Does the 20mg Format Relate to the 10mg and 50mg Formats at iRoids Pharma

The 20mg format delivers double the active compound per tablet compared to the 10mg format and 40 percent of the active compound per tablet compared to the 50mg format. It consequently occupies a practical middle ground between the most conservative and most potent formats in the iRoids Pharma Methandienone range, providing a balance between per-tablet potency and dose precision.

Does Methandienone Aromatize

Yes. Methandienone undergoes significant aromatase-mediated conversion to estradiol. Estrogenic side effects including fluid retention and breast tissue stimulation are consequently primary health considerations at any Methandienone concentration including the 20mg format.

What Are the Most Serious Health Risks at the 20mg Concentration

Hepatotoxicity from 17-alpha alkylation is the most clinically significant health risk and is twice as pronounced per tablet as at the 10mg format. Cardiovascular effects from lipid modification and fluid retention, estrogenic effects from significant aromatization, and HPG suppression complete the primary risk profile. All of these considerations are twice as pronounced per tablet at the 20mg concentration as at the 10mg format. Medical supervision and regular biochemical monitoring are consequently essential for anyone using this compound.

Is Methandienone 20mg Legal to Purchase

Methandienone carries Schedule III controlled substance status in the United States. Legal status varies significantly by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Methandienone 20mg

Methandienone carries one of the most extensively documented pharmacological profiles of any oral anabolic steroid ever produced. The research and clinical observation base accumulated during its period of pharmaceutical availability from 1958 through 1985 provides a meaningful pharmacological reference context that applies to the active compound regardless of the specific concentration format or source.

The 20mg format at iRoids Pharma doubles the per-tablet active compound delivery compared to the 10mg format while providing significantly greater dose precision than the 50mg format. As a result, it occupies a specific practical position between the most conservative and most potent Methandienone formats in our catalog. The clinical research base established at historical pharmaceutical doses of 5mg to 10mg does not directly characterize the side effect profile at 20mg per tablet, making the observational data from non-prescription market use a more relevant reference at this concentration than the controlled clinical literature.

Methandienone carries documented hepatotoxicity, cardiovascular, estrogenic, HPG suppression, androgenic, and psychological health risks. All dose-dependent considerations are twice as pronounced per tablet at the 20mg concentration as at the 10mg format. Medical supervision, regular biochemical monitoring, and informed awareness of the amplified risk profile compared to lower-concentration formats are consequently essential starting points for anyone researching this compound at iRoids Pharma.

For customers in markets where Methandienone is legally available, visit iroidspharma.com to check current Methandienone 20mg availability, pricing, and stock levels.